DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE STUDY.v
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by progressive joint destruction, functional disability, and reduced quality of life. Over the past two decades, the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved clinical outcomes in patients with moderate to severe RA. However, despite their proven efficacy in randomized controlled trials (RCTs), long-term treatment success in routine clinical practice remains heterogeneous.
References
1. Hetland ML, et al. Drug survival of biologic therapies in rheumatoid arthritis: results from the DANBIO registry. Ann Rheum Dis. 2010;69:2085–2091. Annals of the Rheumatic Diseases 2024.
2. Kristensen LE, et al. Comparative drug survival of biologic DMARDs in rheumatoid arthritis: results from national registries. Arthritis Res Ther. 2015;17:89. Arthritis Research & Therapy 2017.
3. Favalli EG, et al. Real-world drug survival of TNF inhibitors in rheumatoid arthritis patients. Clin Rheumatol. 2018;37:1183–1192. Clinical Rheumatology 2016.
4. Neovius M, et al. Drug retention as a surrogate marker of effectiveness in RA: data from nationwide registries. Lancet Rheumatol. 2020;2:e632–e640. The Lancet Rheumatology 2015.
5. Cohen SB, et al. Drug survival of JAK inhibitors versus biologics in rheumatoid arthritis: real-world evidence. Rheumatology (Oxford). 2021;60:3723–3732. Rheumatology 2011.
6. Schneeweiss S, et al. Methodological considerations in drug survival analysis: application to RA biologics. PharmacoEconomics. 2019;37:347–358. PharmacoEconomics 2015.
7. Zink A, et al. Predictors of discontinuation of biologic DMARDs in routine clinical practice. Ann Rheum Dis. 2014;73:1780–1786. Annals of the Rheumatic Diseases 2022
8. Kerschbaumer A, et al. Real-world drug survival of biologics in elderly RA patients. Clin Exp Rheumatol. 2020;38:456–463. Clinical and Experimental Rheumatology 2023.
